Supplementary Figure S3 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors

Prediction-Corrected Visual Predictive Check of a) Relatlimab Concentrations versus Actual Time after Previous Dose and b) Relatlimab trough concentrations versus actual time after first dose in 1L MEL and Prior-IO MEL Patients Who Received 80 mg Q2W and 160 mg Q4W Dosing Regimen (Full Population Pharmacokinetic Model)